We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.

Bruno, R. A., Gasbarrini, A., Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C, <<DIGESTIVE AND LIVER DISEASE>>, 2014; 46 (10): 936-942. [doi:10.1016/j.dld.2014.06.009] [http://hdl.handle.net/10807/60727]

Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C

Bruno, Rosa Anna;Gasbarrini, Antonio
2014

Abstract

We assessed the cost-effectiveness of boceprevir-based triple therapy compared to peginterferon alpha and ribavirin dual therapy in untreated patients with genotype 1 chronic hepatitis C; patients were discriminated according to the combination of baseline plus on-treatment predictors of boceprevir-based triple therapy.
2014
Inglese
Bruno, R. A., Gasbarrini, A., Personalized cost-effectiveness of boceprevir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C, <<DIGESTIVE AND LIVER DISEASE>>, 2014; 46 (10): 936-942. [doi:10.1016/j.dld.2014.06.009] [http://hdl.handle.net/10807/60727]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/60727
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact